Oxford Nanopore Technologies Plc develops proprietary technology platform for the electronic analysis of single molecules. The firm has developed a deoxyribonucleic (DNA)/ ribonucleic acid (RNA) sequencing technology. The Company’s segments include Life Science Research Tools, which offers products and services for research use, and COVID Testing, which provides products for SAR-Cov-2 testing. Its sequencing technology offers real-time analysis, in fully scalable formats from pocket to population scale, that can analyze native DNA or RNA and sequence any length of fragment to achieve short to ultra-long read lengths. Its products include MinION, GridION, PromethION, Flongle and others. MinION is a real-time device for DNA and RNA sequencing. GridION is a benchtop device designed to run and analyze up to five MinION or Flongle Flow Cells. Flongle is an adapter for MinION or GridION that enables direct, real-time DNA sequencing, or cDNA sequencing on smaller, single-use flow cells.
¿Quién es el CEO de Oxford Nanopore Technologies PLC?
Dr. Gurdial Sanghera es el Chief Executive Officer de Oxford Nanopore Technologies PLC, se unió a la empresa desde 2005.
¿Qué tal es el rendimiento del precio de la acción Oxford Nanopore Technologies PL?
El precio actual de Oxford Nanopore Technologies PL es de $1.63, ha disminuido un 1.62% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Oxford Nanopore Technologies PLC?
Oxford Nanopore Technologies PLC pertenece a la industria Life Sciences Tools & Services y el sector es Health Care
¿Cuál es la capitalización bursátil de Oxford Nanopore Technologies PLC?
La capitalización bursátil actual de Oxford Nanopore Technologies PLC es $1.5B
¿Es Oxford Nanopore Technologies PLC una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 15 analistas han realizado calificaciones de análisis para Oxford Nanopore Technologies PLC, incluyendo 5 fuerte compra, 11 compra, 3 mantener, 1 venta, y 5 fuerte venta